Loading...
Loading...
Hemispherx Biopharma, Inc.
HEB (the "Company" or "Hemispherx") filed on July 31, 2012 with the
U.S. Food and Drug Administration its complete response to the FDA's November
25, 2009 Complete Response Letter in support of Ampligen^®'s New Drug
Application for Chronic Fatigue Syndrome ("CFS"). (Please see the Company's
press release and Form 8-K dated August 1, 2012.) On August 10, 2012, the FDA
acknowledged in writing receipt of the Company's August 1, 2012, response
stating, "We consider this a complete, class 2 response to our November 25,
2009, action letter. Therefore, the user fee goal date is February 2, 2013."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in